The first "technology innovation M&A contract" was signed through a public-private partnership M&A platform operated by Korea Technology Finance Corporation (KOTEC).
Korea Technology Finance Corporation (KOTEC) said on the 18th that KOSDAQ-listed AHNGOOK PHARMACEUTICAL signed a technology innovation M&A brokerage contract with the healthcare small and mid-size enterprise Dmedi Korea.
The Korea Technology Finance Corporation (KOTEC) M&A platform is a service that, in collaboration with private brokerage institutions, supports everything from sourcing M&A demand to advisory, brokerage, and financing in one place.
The contract proceeded after AHNGOOK PHARMACEUTICAL expressed interest in buying on the M&A platform. Korea Technology Finance Corporation (KOTEC) linked Inter Capital Partners, which participates on the platform, with AHNGOOK PHARMACEUTICAL and connected specialized advisory services. As a result, an M&A contract between Dmedi Korea and AHNGOOK PHARMACEUTICAL was concluded.
Korea Technology Finance Corporation (KOTEC) noted, "It is significant as the first M&A contract concluded solely through the platform's brokerage and advisory services without separate guarantee support."
AHNGOOK PHARMACEUTICAL plans to continue pursuing strategic acquisitions and alliances in new business areas such as Healthtech and health and beauty (H&B), using this contract as a springboard.
Kim Jong-ho, chair of Korea Technology Finance Corporation (KOTEC), said, "This contract is a successful case in which the public and private sectors cooperated to combine the management capabilities of mid-sized companies with the technological prowess of small and mid-size enterprises," adding, "We will continue, as a policy finance institution, to actively support technology innovation M&A to inject new vitality into the domestic venture exit market."